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schizophrenia from another antipsychotic to
brexpiprazole: comparison of clinicians’ choice of
cross-titration schedules in a post hoc analysis of
a randomized, double-blind, maintenance
treatment study
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Objective.To compare the tolerability and efficacy of different antipsychotic cross-titration schedules, using data from a
brexpiprazole study (Equator; NCT01668797).
Methods. Patients with schizophrenia were cross-titrated from other antipsychotics to brexpiprazole monotherapy in a
1–4 week open-label conversion phase, then entered a single-blind brexpiprazole treatment phase. Patients were
stratified into four “conversion groups,” according to the amount of time spent in the conversion phase.
Discontinuation rates, treatment-emergent adverse events (TEAEs), and efficacy (Positive and Negative Syndrome
Scale [PANSS]) were compared between conversion groups.
Results.Of the 404 patients treated with brexpiprazole, the majority (72.0%) spent 22–33 days in the conversion phase.
Discontinuation rates due to lack of efficacy or adverse events were low in all conversion groups. Of the 292 patients who
successfully switched and completed 8 weeks of brexpiprazole treatment, most were converted to brexpiprazole over 22–
33 days (80.1%), and fewer were converted over 1–7 days (2.4%), 8–14 days (6.5%), or 15–21 days (11.0%). The incidence
of TEAEs over 8 weeks was lower among those converted over 22–33 days (44.4%) than in other conversion groups
(62.5–84.2%), although low patient numbers with shorter conversion times limit the generalizability of this finding. Each
conversion group showed comparable improvement in PANSS total score from baseline.
Conclusion. The majority of patients were cross-titrated to brexpiprazole over a period of 22–33 days, by investigators’
choice. Additional data on shorter conversions may help clinicians to choose a switching paradigm that best meets their
patients’ needs.
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Introduction
Schizophrenia is a severe and chronic disease, with
varying presentation, course, and response to treatment
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among patients. Switching antipsychotic medications is
common in the management of schizophrenia, for
reasons including unsatisfactory response, relapse (despite
compliance), or intolerability due to adverse events.1–4
Many different switching strategies can be conceived,
according to the speed of titration and the degree of
overlap between agents.5 Switching strategies are of
varying complexity and have differing risks of drug
interactions, subtherapeutic dosing, and withdrawal or
rebound symptoms.1,2,5,6 Cross-titration, involving the
gradual dose escalation of a new antipsychotic with
overlapping gradual discontinuation of the previous
antipsychotic,5 is the preferred switching method for oral
atypical antipsychotics according to a panel of experts in
the treatment of schizophrenia.7 In particular, “plateau”
cross-titration, involving the gradual dose escalation of
new antipsychotic with delayed gradual discontinuation of
the previous antipsychotic (only after a therapeutic dose of
the new antipsychotic has been reached and 4–5 half-lives
of the previous antipsychotic have passed), has been
proposed as the best strategy to avoid rebound phenom-
ena,5,8 although this is not supported by current evidence
from randomized controlled trials that may not reflect
patients and treatment strategies in clinical care.9 For
example, plateau cross-titration may minimize the
rebound psychosis, mania, or agitation that can occur
when switching from a full dopamine D2 antagonist to a
partial D2 agonist, and the rebound anxiety, insomnia,
agitation, and restlessness that can occur when switching
from an antipsychotic with more potent antihistaminergic
or anticholinergic activity to one with less antihistaminer-
gic or anticholinergic activity.6,8 Taking into account these
recommendations, individualized switching strategies
should be devised based on the properties of the
antipsychotics involved (e.g., efficacy, tolerability, dosing
schedule, pharmacodynamics, and pharmacokinetics), as
well as patient factors (e.g., past response and severity of
illness).2,8
Brexpiprazole is a serotonin–dopamine activity mod-
ulator that acts as a partial agonist at serotonin 5-HT1A
and dopamine D2 receptors and as an antagonist at
serotonin 5-HT2A and noradrenaline α1B/2C receptors,
all with subnanomolar potency.10 The efficacy and safety
of brexpiprazole have been demonstrated in a phase 3
schizophrenia program comprising two acute stu-
dies11,12 and a maintenance study.13 Brexpiprazole is
approved in the United States, Canada, Australia, and
Japan for the treatment of schizophrenia, and in the
United States as an adjunctive therapy to antidepressants
for the treatment of major depressive disorder.
Due to the design of the acute studies for regulatory
approval, in which patients were washed out from prior
antipsychotics before brexpiprazole was initiated,
these studies generated no data on switching strategies
or outcomes.11,12 In contrast, the brexpiprazole
maintenance study included a 1–4 week conversion
phase in which patients on previous antipsychotic(s)
were cross-titrated to brexpiprazole monotherapy.13 The
aim of the present analysis was to use data from the
maintenance study to compare the tolerability and
efficacy of different clinicians’ choice of cross-titration
schedules to aid clinicians in choosing a switching
schedule to brexpiprazole monotherapy that best meets
their patients’ needs.
Methods
Study design and patients
This was a post hoc analysis of data from a multicenter,
randomized, double-blind, placebo-controlled phase 3
maintenance withdrawal study (Equator;
NCT01668797).13 For a full description of the study
design and selection criteria, please refer to Fleischhacker
and colleagues’ 2017 publication.13 The study was
conducted in accordance with the International Con-
ference on Harmonisation Good Clinical Practice Guide-
line and local regulatory requirements. The protocol was
approved by an institutional review board or independent
ethics committee for each investigational site, and all
patients provided written informed consent to participate.
The study included male and female patients aged
18−65 years with a diagnosis of schizophrenia for at least
3 years as defined by the Diagnostic and Statistical
Manual of Mental Disorders, 4th ed., Text Revision
(DSM-IV-TR)14 and confirmed by the Mini International
Neuropsychiatric Interview (MINI) for Schizophrenia
and Psychotic Disorders Studies.15 Patients had to have
been experiencing an acute exacerbation of psychotic
symptoms at screening, as demonstrated by a Positive
and Negative Syndrome Scale (PANSS)16 total score of
>80. Patients had to have shown a response to
antipsychotic treatment (other than clozapine) in the
previous year, had to be currently being treated with oral
or depot antipsychotics (other than clozapine) or to have
a recent lapse in antipsychotic treatment, and had to
have a history of relapse and/or symptom exacerbation
in the absence of antipsychotic treatment. Exclusion
criteria included a DSM-IV-TR Axis I diagnosis other
than schizophrenia, acute depressive symptoms in the
previous 30 days requiring antidepressant therapy,
antipsychotic-resistant or refractory schizophrenia, a
significant risk of violent behavior or suicide, meeting
DSM-IV-TR criteria for substance abuse or dependence
in the previous 180 days, or requiring prohibited
concomitant therapy during the trial.
The study comprised a screening phase, an open-label
phase for conversion from other antipsychotics to
monotherapy with oral brexpiprazole (and washout of
prohibited concomitant medications), a single-blind
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treatment phase to stabilize patients on oral brexpipra-
zole, a double-blind maintenance treatment phase (in
which patients were randomized to oral brexpiprazole or
placebo), and a safety follow-up phase. Following screen-
ing, eligible patients entered the conversion phase if they
were currently receiving antipsychotics or other prohib-
ited concomitant medications (Table 1); otherwise, they
entered the stabilization phase directly. During the
conversion phase, patients were converted to once-daily
brexpiprazole over 1–4 weeks, as outlined in Table 1.
Simultaneously, previous antipsychotic treatment and
any prohibited medications were discontinued. Patients
completing the conversion phase, and patients not
requiring conversion, entered a 12–36 week stabilization
phase. In this phase, patients were titrated to a dose of
brexpiprazole (1–4mg/d) that would maintain stability
of psychotic symptoms while minimizing tolerability
issues.
This post hoc analysis focused on a time frame of
8 weeks after the first dose of brexpiprazole, covering the
conversion phase and the start of the stabilization phase.
A subsample comprising all patients in whom at least
8 weeks of brexpiprazole treatment was achieved was
chosen to explore: (1) which of the clinicians’ chosen
switching strategies were the most represented among
the successful switches from prior antipsychotic
treatment to brexpiprazole; and (2) whether any baseline
patient or treatment differences existed among the
different naturalistically employed, successful switching
strategies.
Assessments
In this post hoc analysis, tolerability was assessed by the
time to, and reasons for, discontinuation, and the
incidence of treatment-emergent adverse events (TEAEs).
Efficacy was assessed using the PANSS and the Clinical
Global Impressions–Severity of illness (CGI-S) scale. The
PANSS is a clinician-rated scale that measures positive,
negative, and general psychopathology symptoms,
scored from 30 to 210, where a higher score indicates
greater psychopathology.16 The CGI-S is a clinician-
rated scale that measures global illness severity, scored
from 1 (not at all ill) to 7 (among the most extremely
ill).17 The PANSS and CGI-S were administered at the
baseline visit and last visit of the conversion phase and
at every 2 weeks during the stabilization phase.
Statistical analyses
This post hoc analysis included patients who received at
least 1 dose of brexpiprazole during the conversion
TABLE 1. Strategy of switching to brexpiprazole monotherapy during the conversion phase, according to antipsychotic or other prohibited
concomitant medication at screening
Reason for entering conversion phase Switching instructions
Patient was currently receiving oral aripiprazole (dosed within 14 days of screening).
Patient was currently receiving another oral antipsychotic (other than clozapine) (dosed
within 7 days of screening).
Initiate on brexpiprazole 1 mg/d.
Over 1–4 weeks, according to the investigator’s judgment, adjust brexpiprazole
within the range of
1–4 mg/d while gradually reducing the dose of other antipsychotic.
Patient was currently receiving an LAI antipsychotic (dosed within 1.5 cyclesa of
screening).
Initiate on brexpiprazole 1 mg/d.
Over 1–4 weeks, according to the investigator’s judgment, adjust brexpiprazole
within the range of
1–4 mg/d until a time period equal to 1.5 LAI cycles has elapsed.
Patient was currently receiving other prohibited concomitant medications:
♦ all psychotropic agents, including antidepressants, OFC, mood stabilizers, and
benzodiazepinesb
♦ ramelteon and other non-benzodiazepine sleep aidsc
♦ antihistaminesd
♦ varenicline
♦ vitamins, nutritional supplements, and nonprescription herbal preparationse
♦ CYP2D6 inhibitors and CYP3A4 inhibitors and inducers
♦ investigational agents.
Initiate on brexpiprazole 1 mg/d.
Over 1–4 weeks, according to the investigator’s judgment, adjust brexpiprazole
within the range of 1–4 mg/d.
LAI= long-acting injectable; OFC= olanzapine–fluoxetine combination.
a Cycle length was based on the prescribing label. If the required washout was >28 days, the patient was kept in the screening phase for up to 14 days until ≤28 days were
remaining.
b Except lorazepam or oxazepam (clonazepam or diazepam, if not available) used as a rescue medication.
c Except zolpidem, zaleplon, zopiclone, and eszopiclone for the treatment of insomnia.
d Except loratadine and cetirizine.
e Unless approved in advance by the medical monitor.
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phase. Patients were stratified into four “conversion
groups” according to the amount of time spent in the
conversion phase: 1–7 days, 8–14 days, 15–21 days, and
22–33 days (up to 33 days rather than 28 days to allow
for minor variations in visit timings). Patients in each
group were followed for up to 8 weeks from the start of
the conversion phase (their first dose of brexpipra-
zole). Eight weeks of brexpiprazole treatment was
chosen so that patients in each conversion group had
the same exposure to brexpiprazole, and with suffi-
cient time to assess efficacy. Depending on the amount
of time spent in the conversion phase, 8 weeks of
brexpiprazole treatment comprised 1–4 weeks in the
conversion phase and 4–7 weeks in the stabilization
phase (Figure 1).
The four conversion groups were compared in terms
of time to discontinuation for different reasons within
the first 8 weeks of brexpiprazole treatment, plotted as
Kaplan–Meier survival analysis curves. This analysis was
performed to identify any differences in discontinuation
rates according to the speed of cross-titration from a
prior antipsychotic to brexpiprazole.
Next, the conversion groups were further split, as
follows: (1) patients who converted to brexpiprazole
(i.e., completed the conversion phase) and also com-
pleted 8 weeks of brexpiprazole treatment, (2) patients
who converted to brexpiprazole but discontinued in
<8 weeks, and (3) patients who discontinued prior to
converting to brexpiprazole (i.e., discontinued during
the conversion phase). These various subgroups were
generated in order to identify the differences between
patients who successfully converted to brexpiprazole
and those who did not, in terms of reason for
discontinuation, baseline demographic and clinical
characteristics, type of baseline concomitant antipsy-
chotic, and the incidence of TEAEs. Thus, these
analyses were performed to assess the generalizability
of the findings, to identify risk factors for early
discontinuation, and to identify characteristics that
may be less represented in the analyzed sample.
Finally, in the group of patients who converted
to brexpiprazole and completed 8 weeks of brexpiprazole
treatment, the change from baseline in PANSS total
score and CGI-S score were calculated for each conversion
group.
In general, descriptive statistics are presented; due to
the differences in sample size between groups, further
statistical analysis was considered inappropriate. A chi-
squared test was used to assess differences in baseline
concomitant antipsychotic use between groups. One-way
analysis of variance (ANOVA) was used to compare
changes from baseline in PANSS total and CGI-S scores
between conversion groups.
Results
Patient disposition
A total of 404 patients received at least 1 dose of
brexpiprazole during the conversion phase and were
included in this analysis. All patients were currently
receiving at least one antipsychotic other than brexpi-
prazole at baseline, and, therefore, no patients entered
the conversion phase based on prohibited concomitant
medications alone.
Of the 404 patients treated with brexpiprazole
(Figure 1), the majority (72.0%) spent 22–33 days in
the conversion phase. Only a small number of patients
spent 1–7 days (4.2%), 8–14 days (10.4%), or 15–21 days
(13.4%) in the conversion phase.
Times to discontinuation from the start of the
conversion phase to 8 weeks are presented in Figure 2:
(a) due to all reasons other than the sponsor terminated
the study (in this maintenance study, efficacy [as
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• Brexpiprazole 1–4 mg/day
• Washout of prohibited
concomitant medication
• n=404 treated
Stabilization phaseb
• Single-blind
• Brexpiprazole 1–4 mg/day
monotherapy
• n=292 completed 8 weeks
FIGURE 1. Definition of conversion groups, with patient flow through the conversion and stabilization phases. Data for patients who received at least 1 dose of
brexpiprazole in the conversion phase. aWeekly visits; bweekly visits for 4 weeks, every two weeks thereafter.
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measured by the time from randomization to impending
relapse] was demonstrated at a prespecified interim
analysis [conducted after 45 events of impending
relapse], and so the trial was terminated early);13
(b) due to lack of efficacy; and (c) due to adverse events.
Overall, discontinuation rates due to lack of efficacy and
due to adverse events were low, regardless of time spent
in the conversion phase.
In total, 292 (72.3%) of the 404 patients were
converted to brexpiprazole and completed 8 weeks.
Fifty-four patients (13.4%) were converted to brexpipra-
zole but discontinued in <8 weeks, and 58 patients
(14.4%) discontinued prior to converting to brexpipra-
zole. Of the 292 patients who completed 8 weeks of
brexpiprazole treatment, most were converted to brexpi-
prazole over 22–33 days (80.1%), and fewer were
converted over 1–7 days (2.4%), 8–14 days (6.5%), or
15–21 days (11.0%).
Reasons for discontinuation are given in Table 2. For
patients who discontinued in <8 weeks, whether they
converted to brexpiprazole or discontinued prior to
converting, the most common reasons for discontinua-
tion were that the patient withdrew consent and that the
sponsor terminated the study early due to the positive
results of the interim analysis.
Patient characteristics
As shown in Table 3, baseline demographics were
comparable between patients who converted to brexpi-
prazole and completed 8 weeks and patients who
discontinued in <8 weeks (converted or nonconverted).
Regarding clinical characteristics, patients who discon-
tinued in <8 weeks had a higher mean PANSS total score
at baseline than patients who converted and completed
8 weeks (85.2 vs. 81.2).
Among patients who converted and completed
8 weeks, baseline demographic and clinical character-
istics showed a number of inconsistencies between
conversion groups, which should be considered in the
context of the low number of patients in the 1–7 days
(n=7) and 8–14 days (n= 19) groups (Table 3). For
example, the proportions of patients who were female or
who were black were higher in the 1–7 day group (57.1%
and 57.1%, respectively) than in the other conversion
groups (21.9–41.9% and 17.5–26.3%, respectively).
Furthermore, the 1–7 day group had less severe disease
than the other conversion groups, as measured by
PANSS total and Personal and Social Performance (PSP)
scale total scores.
There were no notable differences in patient char-
acteristics between conversion groups for patients who
converted and completed 8 weeks and patients who
discontinued in <8 weeks (data not shown).
Baseline concomitant antipsychotics by conversion
group are listed in Table 4. There were no statistically
significant differences between patients who converted
to brexpiprazole and completed 8 weeks and patients
who discontinued in <8 weeks (converted or noncon-
verted), in terms of the proportion of patients who
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FIGURE 2. Kaplan–Meier curves, by conversion group, of time to
discontinuation during the first 8 weeks of brexpiprazole treatment (a) due
to all reasons other than sponsor terminated study; (b) due to lack of
efficacy; and (c) due to adverse events. Data for patients who received at
least 1 dose of brexpiprazole in the conversion phase.
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TABLE 2. Reasons for brexpiprazole treatment discontinuation, by conversion group, for patients who converted to brexpiprazole but discontinued in
<8 weeks, and for patients who discontinued prior to converting to brexpiprazolea
Converted but discontinued in <8 weeks
n (%) 1–7 days
(n= 3)
8–14 days
(n= 6)
15–21 days
(n= 6)
22–33 days
(n= 39)
Total
(n= 54)
Discontinued 3 (100.0) 6 (100.0) 6 (100.0) 39 (100.0) 54 (100.0)
Patient withdrew consent 0 (0.0) 3 (50.0) 3 (50.0) 12 (30.8) 18 (33.3)
Sponsor terminated study early due to interim analysis 1 (33.3) 1 (16.7) 0 (0.0) 9 (23.1) 11 (20.4)
Adverse event 0 (0.0) 2 (33.3) 1 (16.7) 7 (17.9) 10 (18.5)
Patient met withdrawal criteria 0 (0.0) 0 (0.0) 1 (16.7) 6 (15.4) 7 (13.0)
Lack of efficacy 1 (33.3) 0 (0.0) 0 (0.0) 2 (5.1) 3 (5.6)
Withdrawn by the investigator 0 (0.0) 0 (0.0) 1 (16.7) 2 (5.1) 3 (5.6)
Lost to follow-up 1 (33.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.9)
Protocol deviation 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.6) 1 (1.9)
Discontinued prior to converting
n (%) 1–7 days
(n= 7)
8–14 days
(n= 17)
15–21 days
(n= 16)
22–33 days
(n= 18)
Total
(n= 58)
Discontinued 7 (100.0) 17 (100.0) 16 (100.0) 18 (100.0) 58 (100.0)
Patient withdrew consent 2 (28.6) 4 (23.5) 4 (25.0) 6 (33.3) 16 (27.6)
Sponsor terminated study early due to interim analysis 3 (42.9) 7 (41.2) 6 (37.5) 3 (16.7) 19 (32.8)
Adverse event 1 (14.3) 2 (11.8) 3 (18.8) 2 (11.1) 8 (13.8)
Patient met withdrawal criteria 0 (0.0) 1 (5.9) 0 (0.0) 2 (11.1) 3 (5.2)
Lack of efficacy 0 (0.0) 3 (17.6) 1 (6.3) 3 (16.7) 7 (12.1)
Withdrawn by the investigator 0 (0.0) 0 (0.0) 0 (0.0) 2 (11.1) 2 (3.4)
Lost to follow-up 1 (14.3) 0 (0.0) 1 (6.3) 0 (0.0) 2 (3.4)
Protocol deviation 0 (0.0) 0 (0.0) 1 (6.3) 0 (0.0) 1 (1.7)
a Data for patients who received at least 1 dose of brexpiprazole in the conversion phase.
TABLE 3. Baseline demographic and clinical characteristics, by conversion groupa
Converted and completed 8 weeks Total completed
8 weeks
(n= 292)
Total discontinued in
<8 weeks
(n= 112)Total
(N= 404)
1–7 days
(n= 7)
8–14 days
(n= 19)
15–21 days
(n= 32)
22–33 days
(n= 234)
Demographic characteristics
Age (years), mean (SD) 39.8 (11.3) 39.4 (8.3) 39.2 (11.2) 42.2 (12.6) 39.7 (11.1) 40.0 (11.2) 39.2 (11.5)
BMI (kg/m2), mean (SD) 27.4 (6.1) 28.9 (12.9) 27.5 (6.3) 26.8 (5.1) 27.5 (5.8) 27.5 (6.0) 27.3 (6.4)
Female, n (%) 160 (39.6) 4 (57.1) 6 (31.6) 7 (21.9) 98 (41.9) 115 (39.4) 45 (40.2)
Race, n (%)
White 266 (65.8) 2 (28.6) 11 (57.9) 22 (68.8) 159 (67.9) 194 (66.4) 72 (64.3)
Black/African American 80 (19.8) 4 (57.1) 5 (26.3) 7 (21.9) 41 (17.5) 57 (19.5) 23 (20.5)
Asian 27 (6.7) 0 (0.0) 1 (5.3) 0 (0.0) 21 (9.0) 22 (7.5) 5 (4.5)
Other 31 (7.7) 1 (14.3) 2 (10.5) 3 (9.4) 13 (5.6) 19 (6.5) 12 (10.7)
Clinical characteristics
Age at first diagnosis (years), mean (SD) 26.7 (8.7) 25.6 (6.0) 27.3 (10.8) 28.7 (10.6) 27.0 (8.1) 27.2 (8.5) 25.2 (8.8)
PANSS total score, mean (SD) 81.8 (11.5) 75.3 (11.0) 80.6 (11.4) 83.6 (10.0) 81.1 (12.2) 81.2 (11.9) 85.2 (8.5)
PANSS positive subscale score, mean (SD) 20.3 (4.3) 17.9 (3.5) 20.6 (4.1) 21.5 (3.9) 20.0 (4.4) 20.1 (4.3) 21.1 (4.6)
PANSS negative subscale score, mean (SD) 21.8 (4.6) 19.3 (4.0) 21.5 (4.3) 22.4 (3.3) 21.9 (4.9) 21.8 (4.7) 21.7 (4.3)
PANSS excited component score, mean (SD) 10.7 (3.4) 8.1 (1.9) 9.6 (3.1) 10.7 (3.1) 10.5 (3.3) 10.4 (3.3) 12.0 (3.4)
PSP total score, mean (SD) 47.2 (11.2) 64.3 (14.5) 41.9 (10.1) 47.7 (9.0) 46.6 (11.1) 46.9 (11.1) 48.0 (11.4)
(n= 189) (n= 3) (n= 7) (n= 18) (n= 107) (n= 135) (n= 54)
CGI-S score, mean (SD) 4.2 (0.7) 4.0 (0.6) 4.2 (0.7) 4.2 (0.6) 4.1 (0.8) 4.1 (0.8) 4.3 (0.6)
BMI= body mass index; CGI-S= Clinical Global Impressions–Severity of illness; PANSS= Positive and Negative Syndrome Scale; PSP= Personal and Social Performance scale;
SD= standard deviation.
a Data for patients who received at least 1 dose of brexpiprazole in the conversion phase.
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TABLE 4. Concomitant antipsychotics from which patients were switched to brexpiprazole during the conversion phase, by conversion groupa
Converted and completed 8 weeks
Concomitant antipsychotics Total
(N= 404),
n (%)
1–7 days
(n= 7),
n (%)
8–14 days
(n= 19),
n (%)
15–21 days
(n= 32),
n (%)
22–33 days
(n= 234),
n (%)
p value comparing the four
conversion groupsb
Total completed
8 weeks
(n= 292),
n (%)
Total discontinued in
<8 weeks
(n = 112),
n (%)
p value comparing total completed 8 weeks and
total discontinued in <8 weeksb
Relatively strong antihistaminergic and/or anticholinergic properties 173 (42.8) 2 (28.6) 6 (31.6) 11 (34.4) 102 (43.6) 0.50 121 (41.4) 52 (46.4) 0.36
Olanzapine 77 (19.1) 1 (14.3) 3 (15.8) 3 (9.4) 53 (22.6) 60 (20.5) 17 (15.2)
Quetiapinec 73 (18.1) 1 (14.3) 3 (15.8) 4 (12.5) 39 (16.7) 47 (16.1) 26 (23.2)
Chlorpromazine 25 (6.2) 0 (0.0) 0 (0.0) 3 (9.4) 11 (4.7) 14 (4.8) 11 (9.8)
Clozapine 7 (1.7) 0 (0.0) 0 (0.0) 1 (3.1) 3 (1.3) 4 (1.4) 3 (2.7)
Relatively strong antidopaminergic properties 283 (70.0) 5 (71.4) 12 (63.2) 25 (78.1) 163 (69.7) 0.69 205 (70.2) 78 (69.6) 0.91
Risperidone 137 (33.9) 1 (14.3) 8 (42.1) 17 (53.1) 72 (30.8) 98 (33.6) 39 (34.8)
Haloperidol 56 (13.9) 2 (28.6) 0 (0.0) 3 (9.4) 32 (13.7) 37 (12.7) 19 (17.0)
Aripiprazole 44 (10.9) 2 (28.6) 3 (15.8) 4 (12.5) 25 (10.7) 34 (11.6) 10 (8.9)
Trifluoperazined 17 (4.2) 0 (0.0) 1 (5.3) 0 (0.0) 11 (4.7) 12 (4.1) 5 (4.5)
Zuclopenthixole 17 (4.2) 0 (0.0) 0 (0.0) 0 (0.0) 11 (4.7) 11 (3.8) 6 (5.4)
Amisulpride 16 (4.0) 0 (0.0) 0 (0.0) 1 (3.1) 11 (4.7) 12 (4.1) 4 (3.6)
Chlorprothixenef 13 (3.2) 0 (0.0) 0 (0.0) 2 (6.3) 8 (3.4) 10 (3.4) 3 (2.7)
Ziprasidone 8 (2.0) 0 (0.0) 0 (0.0) 1 (3.1) 6 (2.6) 7 (2.4) 1 (0.9)
Fluphenazineg 8 (2.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.3) 3 (1.0) 5 (4.5)
Paliperidone 7 (1.7) 1 (14.3) 0 (0.0) 0 (0.0) 4 (1.7) 5 (1.7) 2 (1.8)
Flupentixol 5 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.3) 3 (1.0) 2 (1.8)
Perphenazine 3 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.9) 2 (0.7) 1 (0.9)
Asenapine 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.9) 2 (0.7) 0 (0.0)
Iloperidone 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.3) 1 (0.9)
Long-acting injectable 11 (2.7) 0 (0.0) 0 (0.0) 0 (0.0) 9 (3.8) 0.51 9 (3.1) 2 (1.8) 0.47
Flupentixol decanoate 5 (1.2) 0 (0.0) 0 (0.0) 0 (0.0) 5 (2.1) 5 (1.7) 0 (0.0)
Haloperidol decanoate 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.3) 1 (0.9)
Paliperidone palmitate 2 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.3) 1 (0.9)
Fluphenazine enanthate 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.3) 0 (0.0)
Zuclopenthixol decanoate 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.3) 0 (0.0)
Unknown antipsychotic 7 (1.7) 0 (0.0) 1 (5.3) 0 (0.0) 4 (1.7) 5 (1.7) 2 (1.8)
a Data for patients who received at least 1 dose of brexpiprazole in the conversion phase. Patients may have received more than one concomitant antipsychotic. Antipsychotics are grouped according to their pharmacodynamic properties, as previously described8 or
as defined by the authors.
b p values were calculated using a chi-squared test.
c Quetiapine or quetiapine fumarate.
d Trifluoperazine or trifluoperazine hydrochloride.
e Zuclopenthixol, zuclopenthixol acetate, or zuclopenthixol hydrochloride.
f Chlorprothixene or chlorprothixene hydrochloride.
g Fluphenazine or fluphenazine hydrochloride.
SW
ITCHING
TO
BREXPIPRAZOLE
IN
SCHIZOPHRENIA
7
https://doi.org/10.1017/S1092852918001086
D
ow
nloaded from
 https://w
w
w
.cam
bridge.org/core. H
ofstra U
niversity, on 19 Jul 2019 at 14:11:38, subject to the C
am
bridge C
ore term
s of use, available at https://w
w
w
.cam
bridge.org/core/term
s.
switched from antipsychotics with relatively strong
antihistaminergic/anticholinergic or antidopaminergic
properties or long-acting injectable (LAI)
antipsychotics.
Among patients who converted and completed
8 weeks, there were no statistically significant differ-
ences between conversion groups in terms of the
proportion of patients who switched from antipsychotics
with relatively strong antihistaminergic/anticholinergic
or antidopaminergic properties (Table 4). Similar non-
statistically significant differences between conversion
groups were observed for patients who discontinued in
<8 weeks (data not shown).
TEAEs
The incidence of TEAEs was comparable between the
patients who converted to brexpiprazole and completed
8 weeks (49.7%) and the patients who discontinued in
<8 weeks (converted or nonconverted) (47.3%),
although the latter group, by definition, spent less time
on brexpiprazole.
TEAEs with incidence≥2.0% during the first 8 weeks
of brexpiprazole treatment are listed in Table 5 and
Supplementary Table 1. Across all patients, the most
common individual TEAEs (incidence≥5%) were insom-
nia (11.1%), headache (7.2%), agitation (6.2%), and
akathisia (5.2%).
Among patients who converted and completed
8 weeks, the incidence of TEAEs over 8 weeks was lower
among those converted over 22–33 days (44.4%) than in
the other conversion groups (62.5–84.2%).
Efficacy
Changes from baseline in PANSS total and CGI-S scores
are presented in Table 6. Among patients who converted
to brexpiprazole and completed 8 weeks, each conver-
sion group showed improvements in PANSS total and
CGI-S scores from baseline to stabilization phase weeks
4, 6, and 8. There were no statistically significant
differences in the magnitude of improvement from
baseline between the conversion groups.
Discussion
In this post hoc analysis of a long-term, controlled
clinical study of brexpiprazole as maintenance treatment
for schizophrenia, patients were converted from previous
antipsychotic(s) to brexpiprazole monotherapy over a
time period of 1–4 weeks, according to the investigators’
judgment (and the protocol-defined washout of prohib-
ited concomitant medications). The majority of patients
whowere successfully switched and completed 8 weeks of
brexpiprazole treatment were converted from previous
antipsychotic(s) to brexpiprazole monotherapy over a
TABLE 5. Treatment-emergent adverse events (TEAEs) in the 8 weeks from the start of the conversion phase (the first dose of brexpiprazole), by
conversion groupa
Converted and completed 8 weeks Total completed
8 weeks
(n= 292)
Total discontinued in
<8 weeks
(n= 112)n (%) Total
(N= 404)
1–7 days
(n= 7)
8–14 days
(n= 19)
15–21 days
(n= 32)
22–33 days
(n= 234)
Any TEAE 198 (49.0) 5 (71.4) 16 (84.2) 20 (62.5) 104 (44.4) 145 (49.7) 53 (47.3)
TEAEs with incidence≥2.0% in the “total completed 8 weeks” or “total discontinued in <8 weeks” groups
Insomnia 45 (11.1) 2 (28.6) 3 (15.8) 7 (21.9) 27 (11.5) 39 (13.4) 6 (5.4)
Headache 29 (7.2) 1 (14.3) 3 (15.8) 2 (6.3) 14 (6.0) 20 (6.8) 9 (8.0)
Agitation 25 (6.2) 1 (14.3) 1 (5.3) 2 (6.3) 12 (5.1) 16 (5.5) 9 (8.0)
Akathisia 21 (5.2) 0 (0.0) 1 (5.3) 2 (6.3) 13 (5.6) 16 (5.5) 5 (4.5)
Nasopharyngitis 18 (4.5) 0 (0.0) 3 (15.8) 1 (3.1) 10 (4.3) 14 (4.8) 4 (3.6)
Nausea 13 (3.2) 0 (0.0) 1 (5.3) 1 (3.1) 7 (3.0) 9 (3.1) 4 (3.6)
Dizziness 10 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 8 (3.4) 8 (2.7) 2 (1.8)
Tremor 10 (2.5) 0 (0.0) 0 (0.0) 2 (6.3) 4 (1.7) 6 (2.1) 4 (3.6)
Diarrhea 9 (2.2) 1 (14.3) 1 (5.3) 0 (0.0) 5 (2.1) 7 (2.4) 2 (1.8)
Schizophrenia 9 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.3) 8 (7.1)
Extrapyramidal disorder 8 (2.0) 0 (0.0) 1 (5.3) 2 (6.3) 5 (2.1) 8 (2.7) 0 (0.0)
Constipation 8 (2.0) 0 (0.0) 3 (15.8) 2 (6.3) 1 (0.4) 6 (2.1) 2 (1.8)
Vomiting 7 (1.7) 1 (14.3) 1 (5.3) 1 (3.1) 3 (1.3) 6 (2.1) 1 (0.9)
Abdominal discomfort 6 (1.5) 1 (14.3) 1 (5.3) 1 (3.1) 3 (1.3) 6 (2.1) 0 (0.0)
Upper respiratory tract infection 6 (1.5) 1 (14.3) 0 (0.0) 1 (3.1) 4 (1.7) 6 (2.1) 0 (0.0)
a Data for patients who received at least 1 dose of brexpiprazole in the conversion phase.
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period of 22–33 days. Regardless of the conversion
schedule, the rates of discontinuation due to lack of
efficacy or due to adverse events were low and showed
only small differences. In other words, groups of patients
with whom clinicians attempted conversion over shorter
time periods were no more likely to discontinue than
groups for whom conversion was attempted over longer
time periods. It is unclear if clinicians used unmeasured
patient characteristics to preselect patients in whom they
attempted a shorter conversion schedule during the
switch to brexpiprazole. Similarly, it remains unclear
whether clinicians chose the conversion schedules a
priori, or if they prolonged the conversion period in
patients who experienced emergent symptoms or pro-
blems. There was a numerically higher incidence of
TEAEs over 8 weeks among patients who converted to
brexpiprazole over 1–7 days and 8–14 days than among
those who converted over 22–33 days, but the low
number of patients in these groups limits between-group
interpretations.
Oral antipsychotics were cross-titrated over 1–4 weeks
and, within the defined 1–4 week window, clinicians used
their judgment regarding the up-titration of brexpipra-
zole and the down-titration of previous antipsychotic:
there was no defined schedule for dose escalation of
brexpiprazole, delay prior to discontinuation of previous
antipsychotic, or rate of discontinuation of previous
antipsychotic. LAI antipsychotics were stopped abruptly
prior to brexpiprazole initiation, which, due to the long
half-lives of LAIs, can be equated to cross-titration.18,19
Antipsychotic switching may be complicated by potential
pharmacodynamic and pharmacokinetic withdrawal
and rebound phenomena when switching from a highly
antihistaminergic/anticholinergic antipsychotic to a
less antihistaminergic/anticholinergic antipsychotic, to
a partial D2 agonist from a full D2 antagonist, or to an
antipsychotic with a longer half-life from one with a
shorter half-life.2,8 Because brexpiprazole is a D2 partial
agonist with minimal antihistaminergic/anticholinergic
properties, investigators may have chosen longer conver-
sion periods to avoid these potential withdrawal and
rebound phenomena.8,10 In general, switching strategies
with overlap between the two agents may be the most
beneficial to avoid intra-switch worsening/complications.
In clinical practice, however, a longitudinal study in the
Netherlands showed that the majority of antipsychotics
are switched abruptly.20 Furthermore, an open-label study
of switching to aripiprazole (another D2 partial agonist)
from other antipsychotics found no safety differences
between abrupt switching and cross-titration.21
Prior studies have not always shown a difference
between switching strategies,9,22,23 for reasons that may
include the hospitalization status of patients, benzodia-
zepine use (often permitted but unmeasured) that could
counter rebound phenomena, and the differing pharma-
cologic profiles of pre-switch antipsychotics. A meta-
analysis of five randomized controlled studies comparing
plateau cross-titration with nondelayed cross-titration in
patients with schizophrenia found no statistically sig-
nificant differences on any clinical outcomes, including
discontinuation rate, psychopathology, extrapyramidal
symptoms, and TEAEs.9 The individual randomized
TABLE 6. Change from baseline in PANSS total score and CGI-S score with brexpiprazole treatment, by conversion groupa
Converted and completed 8 weeks
1–7 days
(n= 7)
8–14 days
(n= 19)
15–21 days
(n= 32)
22–33 days
(n= 234)
p value comparing the
four conversion groupsb
Mean (SD) PANSS total score at baseline 75.3 (11.0) 80.6 (11.4) 83.6 (10.0) 81.1 (12.2)
Mean (SD) change in PANSS total score from baseline to:
Stabilization phase week 4 − 19.6 (11.2) − 21.6 (13.6) − 15.3 (6.6) − 17.5 (11.4)e 0.2557
Stabilization phase week 6 − 18.6 (14.5) − 22.8 (13.9) − 17.0 (8.6)c − 19.2 (11.7)f 0.3932
Stabilization phase week 8 − 21.3 (13.1) − 23.8 (17.1) − 19.6 (10.6)d − 20.6 (12.2)g 0.7012
Mean (SD) CGI-S score at baseline 4.0 (0.6) 4.2 (0.7) 4.2 (0.6) 4.1 (0.8)
Mean (SD) change in CGI-S score from baseline to:
Stabilization phase week 4 − 1.0 (0.8) − 1.2 (0.8) − 0.8 (0.7) − 0.8 (0.8)e 0.1894
Stabilization phase week 6 − 0.9 (0.7) − 1.3 (0.9) − 0.8 (0.7)c − 0.9 (0.8)f 0.3135
Stabilization phase week 8 − 1.0 (0.8) − 1.3 (1.0) − 1.1 (0.7)d −1.0 (0.8)g 0.3213
CGI-S= Clinical Global Impressions–Severity of illness; PANSS= Positive and Negative Syndrome Scale; SD= standard deviation.
a Data for patients who received at least 8 weeks of brexpiprazole treatment.
b p values were calculated using one-way analysis of variance.
c n= 30.
d n= 27.
e n= 226.
f n= 215.
g n= 199.
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controlled trials included in the meta-analysis also failed
to show the superiority of either switching strategy.9
However, in the meta-analysis, data for all antipsychotics
were pooled together, independent of their pharmacoki-
netic and pharmacodynamic properties, and the different
pharmacologic properties of the baseline, pre-switch
antipsychotics were similarly not considered, which may
have obscured differences across switching strategies.
While not reflecting real-world clinical practice, these
inconclusive findings seem to indicate that it may be
difficult to generalize switching approaches (each patient
may require an individualized switching strategy) and that
switching strategies may especially differ for switches
between antipsychotics with similar versus different
pharmacologic properties.8 The current meta-analyses
on switching did not have sufficient power to adequately
address this issue, and future studies are needed for
clarification, particularly now that three different partial
D2 agonists are available for which switches from full D2
antagonists would at least theoretically be complicated by
an interaction between partial D2 agonism and an
upregulated D2 receptor system.8
In the present analysis, the efficacy of brexpiprazole
was similar in all conversion groups, as demonstrated by
improvements from baseline to stabilization phase weeks
4, 6, and 8 in PANSS total and CGI-S scores. Because
patients were cross-titrated from a wide variety of
antipsychotic drugs, the improvements in PANSS total
and CGI-S indicate that conversion to brexpiprazole may
be efficacious for acutely ill patients (who received at
least 8 weeks of brexpiprazole treatment) regardless of
their prior therapy or the switching schedule.
Limitations of the present analysis include: (1) that
the switching strategy/duration of overlap was the
clinicians’ choice and not randomized, yet this feature
also increases the real-world applicability and general-
izability of the findings; (2) the exploratory, post hoc
nature of the analyses; (3) the low numbers of patients
who were converted to brexpiprazole over 1–7 and 8–
14 days, which mandates caution when interpreting the
findings that improvements in efficacy appeared to be
irrespective of conversion rate; (4) the multiplicity of
baseline antipsychotics, precluding a more definitive
assessment beyond pharmacologically similar subgroups
of antipsychotics as to whether the switch from any specific
antipsychotic with specific pharmacodynamic and pharma-
cokinetic properties would be more or less problematic/
associated with withdrawal or rebound phenomena when
switching to brexpiprazole; and (5) the lack of information
from clinicians about the reasons for the switching strategy
employed. Strengths of the study include the overall size
of the study population; the structured study phases and
assessments; and the real-world decision-making regarding
the switching strategy employed (within the protocol-
specified 1–4 week duration).
Conclusions
The results presented here provide a mostly clinically
driven evidence base from which clinicians can choose a
switching paradigm for patients initiating brexpiprazole
that best meets their patients’ needs. In general, for a
successful switch entailing at least 8 weeks of brexpipra-
zole treatment, a longer switching period of 22–33 days
was employed and was efficacious. Additional, real-world
data on preferred and successful switching strategies
could be helpful to inform clinicians’ optimal use of
brexpiprazole in patient subgroups when converting
treatment from specific other antipsychotics.
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